These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15758629)

  • 1. Octreotide therapy for advanced hepatocellular carcinoma.
    Slijkhuis WA; Stadheim L; Hassoun ZM; Nzeako UC; Kremers WK; Talwalkar JA; Gores GJ
    J Clin Gastroenterol; 2005 Apr; 39(4):333-8. PubMed ID: 15758629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
    Samonakis DN; Christodoulakis N; Kouroumalis EA
    J Clin Gastroenterol; 2006 Jan; 40(1):86-7. PubMed ID: 16340641
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
    Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
    Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
    Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
    Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
    Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
    Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.
    Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E
    Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial.
    Longo F; De Filippis L; Zivi A; Vitolo D; Del Signore E; Gori B; Diso D; Anile M; Venuta F; De Giacomo T; Coloni CF
    Am J Clin Oncol; 2012 Apr; 35(2):105-9. PubMed ID: 21325939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete regression of advanced HCC with long acting octreotide.
    Siveke JT; Herberhold C; Folwaczny C
    Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151
    [No Abstract]   [Full Text] [Related]  

  • 16. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study.
    Schöniger-Hekele M; Kettenbach J; Peck-Radosavljevic M; Müller C
    J Exp Clin Cancer Res; 2009 Nov; 28(1):142. PubMed ID: 19887008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
    Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
    Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
    Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
    Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial.
    Müller C; Schöniger-Hekele M; Schernthaner R; Renner B; Peck-Radosavljevic M; Brichta A; Wrba F; Posch M; Bauer P; Ferenci P; Gangl A
    Wien Klin Wochenschr; 2008; 120(19-20):608-18. PubMed ID: 19083165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature.
    Gill ML; Atiq M; Sattar S; Khokhar N
    J Pak Med Assoc; 2005 Apr; 55(4):135-8. PubMed ID: 15918622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.